急性单核细胞白血病迭患多发性骨髓瘤一例并文献复习
Simultaneous Occurrence of Acute Myeloid Leukemia and Multiple Myeloma: A Case Report and Literature Review
摘要: 目的：探讨急性髓系白血病迭患多发性骨髓瘤的发生机制、治疗方法及预后。方法：对1例急性单核细胞白血病迭患多发性骨髓瘤患者的病例资料进行分析，并复习相关文献。结果：该例患者行小剂量地西他滨 + 阿克拉霉素 + VRd方案化疗2疗程，小剂量地西他滨 + CAG + 硼替佐米方案化疗1疗程，最终因原发病进展合并严重感染死亡，生存期10个月。结论：此类病例临床罕见，预后差，临床多为个案报道，目前治疗方案仍不能治愈大多数患者，化疗序贯移植或联合新的靶向药物有望延长患者生存期，改善预后。
Abstract: Objective: To investigate the pathogenesis, treatment and prognosis of simultaneous occurrence of acute myeloid leukemia and multiple myeloma. Methods: The case data of a patient with acute monocytic leukemia complicated with multiple myeloma were analyzed and the related literatures were reviewed. Result: The patient was treated with low dose of decitabine + aclacinomycin + VRd for two courses of chemotherapy, low dose of decitabine + aclacinomycin + bortezomib for one course of chemotherapy. Finally, he died of progression of primary disease with severe infection and survived for 10 months. Conclusion: Such cases are rare in clinic and poor in prognosis, but most of them are reported in individual cases. At present, the treatment scheme cannot cure most patients. Sequential transplantation of chemotherapy or combined with new targeted drugs is expected to prolong the survival time of patients and improve the prognosis.
文章引用：李智慧, 李丽, 王彦丽. 急性单核细胞白血病迭患多发性骨髓瘤一例并文献复习[J]. 临床医学进展, 2022, 12(1): 376-380. https://doi.org/10.12677/ACM.2022.121057

参考文献

[1] Chirlaque, M., Chen-Liang, T.H., Hurtado, A.M., García Malo, M.D., Ortuño, F.J., Roldán, V., Vicente, V., Jerez, A. and De Arriba, F. (2019) Increasing Therapy-Related Myeloid Neoplasms in Multiple Myeloma. European Journal of Clinical Investigation, 49, Article ID: e13050. [Google Scholar] [CrossRef] [PubMed]
[2] Mailankody, S., Pfeiffer, R.M., Kristinsson, S.Y., Korde, N., Bjorkholm, M., Goldin, L.R., Turesson, I. and Landgren, O. (2011) Risk of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Multiple Myeloma and Its Precursor Disease (MGUS). Blood, 118, 4086-4092. [Google Scholar] [CrossRef] [PubMed]
[3] Bhatia, S. (2013) Therapy-Related Myelodysplasia and Acute Myeloid Leukemia. Seminars in Oncology, 40, 666-675. [Google Scholar] [CrossRef] [PubMed]
[4] Chung, A. and Liedtke, M. (2019) Therapy-Related Myeloid Neoplasms after Treatment for Plasma-Cell Disorders. Best Practice & Research Clinical Haematologyl, 32, 54-64. [Google Scholar] [CrossRef] [PubMed]
[5] Gupta, S.K., Chandramohan, J. and Kumar, L. (2015) AML Transformation after Autologous Stem Cell Transplant for Multiple Myeloma. BMJ Case Reports, 2015, Article ID: bcr2015210024. [Google Scholar] [CrossRef] [PubMed]
[6] Nepstad, I., Hatfield, K.J., Grønningsæter, I.S. and Reikvam, H. (2020) The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cell12s. International Journal of Molecular Sciences, 21, Article No. 2907. [Google Scholar] [CrossRef] [PubMed]
[7] Ramakrishnan, V. and Kumar, S. (2018) PI3K/AKT/mTOR Pathway in Multiple Myeloma: From Basic Biology to Clinical Promise. Leukemia & Lymphoma, 59, 2524-2534. [Google Scholar] [CrossRef] [PubMed]
[8] Harms, M., Gilg, A., Ständker, L., Beer, A.J., Mayer, B., Rasche, V., Gruber, C.W. and Münch, J. (2020) Microtiter Plate-Based Antibody-Competition Assay to determine binding affinities and Plasma/Blood Stability of CXCR4 Ligands. Scientific Reports, 10, Article No. 16036. [Google Scholar] [CrossRef] [PubMed]
[9] Ullah, T.R. (2019) The Role of CXCR4 in Multiple Myeloma: Cells’ Journey from Bone Marrow to Beyond. Journal of Bone Oncology, 17, Article ID: 100253. [Google Scholar] [CrossRef] [PubMed]
[10] Cory, S., Huang, D.C. and Adams, J.M. (2003) The Bcl-2 Family: Roles in Cell Survival and Oncogenesis. Oncogene, 22, 8590-8607. [Google Scholar] [CrossRef] [PubMed]
[11] Linden, M. (2004) Targeted Overexpression of Bcl-XL in B-Lymphoid Cells Results in Lymphoproliferative Disease and Plasma Cell Malignancies. Blood, 103, 2779-2786. [Google Scholar] [CrossRef] [PubMed]
[12] Bolli, N., Biancon, G., Moarii, M., Gimondi, S., Li, Y., de Philippis, C., et al. (2018) Analysis of the Genomic Landscape of Multiple Myeloma Highlights Novel Prognostic Markers and Disease Subgroups. Leukemia, 32, 2604-2616. [Google Scholar] [CrossRef] [PubMed]
[13] Oka, S., Ono, K. and Nohgawa, M. (2017) Successful Treatment with Azacitidine for the Simultaneous Occurrence of Multiple Myeloma and Acute Myeloid Leukemia with Concomitant del(5q) and the JAK2 V617F Mutation. Annals of Hematology, 96, 1411-1413. [Google Scholar] [CrossRef] [PubMed]
[14] Kumar, R., Srinivasan, V.K., Sharma, P., Aggarwal, R., Prakash, G., Malhotra, P. and Varma, N. (2016) Synchronous Plasma Cell Myeloma and Acute Myeloid Leukemia in a Therapy-Naïve Patient: A Rare Occurrence. Indian Journal of Hematology and Blood Transfusion, 32, 168-172. [Google Scholar] [CrossRef] [PubMed]
[15] Kim, D., Kwok, B. and Steinberg, A. (2010) Simultaneous Acute Myeloid Leukemia and Multiple Myeloma Successfully Treated with Allogeneic Stem Cell Transplantation. Southern Medical Journal, 103, 1246-1249. [Google Scholar] [CrossRef] [PubMed]
[16] Murukutlaa, S., Aroraa, S., Bhatta, V.R., Kediaa, S., Popalzaib, M. and Dhar, M. (2014) Concurrent Acute Monoblastic Leukemia and Multiple Myeloma in a 66-Year-Old Chemotherapy-Naive Woman. World Journal of Oncology, 5, 68-71. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, L.-Q., Hao, L., Li, X.-X., Li, F.-L., Wang, L.-L., Chen, X.-L. and Hou, M. (2015) A Case of Simultaneous Occurrence of Acute Myeloid Leukemia and Multiple Myeloma. BMC Cancer, 15, Article No. 724. [Google Scholar] [CrossRef] [PubMed]
[18] Berthon, C., Nudel, M., Boyle, E.M., Goursaud, L., Boyer, T., Marceau, A. and Quesnel, B. (2020) Acute Myeloid Leukemia Synchronous with Multiple Myeloma Successfully Treated by Azacytidine/Lenalidomide and Daratumumab without a Decrease in Myeloid Clone Size. Leukemia Research Reports, 13, Article ID: 100202. [Google Scholar] [CrossRef] [PubMed]
[19] El-Shakankiry, N.H., El-Sayed, G.M., El-Maghraby, S. and Moneer, M.M.. (2009) Bcl-2 Protein Expression In Egyptian Acute Myeloid Leukemia. Journal of the Egyptian National Cancer Institute, 21, 71-76.
[20] Campos, L., Rouault, J.P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., et al. (2002) High Expression of Bcl-2 Protein in Acute Myeloid Leukemia Cells Is Associated with Poor Response to Chemotherapy. Blood, 81, 3091-3096.
[21] Zhang, H., Wilmot, B., Bottomly, D., Kurtz, S.E., Eide, C.A., Damnernsawad, A., et al. (2018) Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment. Blood, 132, 175. [Google Scholar] [CrossRef] 
[22] Mill, C.P., Cai, T., Fiskus, W., Borthakur, G., Kornblau, S.M., Kadia, T.M., et al. (2018) Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells. Blood, 132, 1351. [Google Scholar] [CrossRef] 
[23] Punnoose, E.A., Leverson, J.D., Peale, F., Boghaert, E.R., Belmont, L.D., Tan, N., et al. (2016) Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Molecular Cancer Therapeutics, 15, 1132-1144. [Google Scholar] [CrossRef] [PubMed]
[24] Touzeau, C., Maciag, P., Amiot, M. and Moreau, P. (2018) Targeting Bcl-2 for the Treatment of Multiple Myeloma. Leukemia, 32, 1899-1907. [Google Scholar] [CrossRef] [PubMed]
[25] Kumar, S.K., Harrison, S.J., Cavo, M. de la Rubia, J., Popat, R., Gasparetto, C, et al. (2020) Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial. The Lancet Oncology, 21, 1630-1642. [Google Scholar] [CrossRef] [PubMed]
[26] Guerra, V.A., Di Nardo, C. and Konopleva, M., (2019) Venetoclax-Based Therapies for Acute Myeloid Leukemia. Best Practice and Research in Clinical Haematology, 32, 145-153. [Google Scholar] [CrossRef] [PubMed]
[27] Tron, A.E., Belmonte, M.A., Adam, A., Aquila, B.M., Boise, L.H., Chiarparin, E., et al. (2018) Discovery of Mcl-1-Specific Inhibitor AZD5991 and Preclinical Activity in Multiple Myeloma and Acute Myeloid Leukemia. Nature Communications, 9, Article No. 5341. [Google Scholar] [CrossRef] [PubMed]

为你推荐